Graves' Ophthalmopathy

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Immunovant
ImmunovantDURHAM, NC
1 program
1
RVT-1401Phase 21 trial
Active Trials
NCT03922321CompletedEst. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ImmunovantRVT-1401

Clinical Trials (1)

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

Start: Apr 2019Est. completion: May 2020
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space